GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...

Dec 17 (Reuters) - Insmed (INSM.O), opens new tab said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to ...

Insmed Inc. shares sunk in late trading Wednesday after the company said its drug to treat a sinus condition failed in a mid-stage trial — a rare setback for the fast-growing biotech. The company had ...

Credit: Getty Images Researchers evaluated adults with severe CRSwNP who had used tezepelumab to determine whether treatment effects continued after treatment ceased. Among patients with CRSwNP who ...

Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men. HealthDay News — Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Tezepelumab-ekko is now approved for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting thymic stromal lymphopoietin and marking its second indication after severe asthma. The phase 3 ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...